Forget the glossy press releases. The true impact of science and tech initiatives in Kano reveals a deeper geopolitical struggle over digital sovereignty.
The journey from academic 'eureka' to commercial patent is broken. We dissect the hidden costs of **technology transfer** and **intellectual property** management.
Gilead's massive $7.8bn acquisition of Arcellx isn't just about pipeline depth; it’s a brutal market consolidation signal in the competitive **biotech M&A** landscape.
Syndex Bio's $15.5M seed funding and mcPCR reveal the truth about next-gen sequencing bottlenecks.
Forget Silicon Valley hype. The real disruption in African technology is brewing not in coding bootcamps, but within design faculties like Tshwane University of Technology's, signaling a crucial shift in digital innovation.
Unpacking the true winners and losers in the latest Iiiag Technology Investment UK push. It's not about innovation; it's about jurisdiction.
The mounting losses for GSI Technology (GSIT) investors reveal a brutal truth about small-cap defense tech and speculative trading.
Norway's Kilter just raised €6.5M for precision weeding, but this 'Green Tech' masks a deeper crisis in **agritech investment** and labor.
The slow erosion of **science funding** isn't an accident; it's a strategy. Unpacking the hidden winners in the war on **research grants** and **scientific advancement**.
Beyond the headlines of hair regrowth and ancient DNA, this week in science reveals a dangerous trend: trivializing genuine biological trauma.
The inevitable AI hype correction of 2025 isn't about failure; it's about resource reallocation. Prepare for the pivot.
Forget the doom-and-gloom narratives. Apple, Microsoft, and OpenAI's massive Irish investments signal a dangerous, hyper-concentrated shift in global **technology employment**.